TBI occurs when a sudden trauma results in damage to the brain. It is one of the most common causes of disability and death in adults. TBI patients are classified as either mild, moderate or severe, depending on the extent of damage.

There are approximately 4 million TBIs in the U.S. each year. It is estimated that as many as 50% of mild TBIs (concussions) may go unreported.¹ There are also an estimated additional 45 million TBIs occurring globally.

NTS-104 will initially be studied in a sub-population of TBI patients having intracranial abnormalities visible on CT imaging, defined as a complicated mild traumatic brain injury (CmTBI).

*Definitions: CmTBI is Complicated mild TBI as defined by GCS 13-15 with positive head CT findings

Sources: U.S. Center for Disease Control; The Lancet Neurology Commission

1. Harmon, Kimberly G., et al. “American Medical Society for Sports Medicine Position Statement.” Clinical Journal of Sport Medicine, vol. 23, no. 1, 2013, pp. 1–18., doi:10.1097/jsm.0b013e31827f5f93.

TBI Epidemiology, Symptoms, and Economic Burden

Sources: Center for Disease Control; U.S. Food & Drug Administration; The Lancet; Journal of Neurosurgery

NTS is targeting treatment of MILD TBI (Concussion)

NTS clinical studies will include advanced patient stratification models, early and extended outcome assessment, and utilize a global network of neurotrauma centers. Hover over the boxes to learn more about NTS’ clinical trial study design.